New
Afilaria 3.4 mg/ml View larger

Afilaria 3.4 mg/ml

New product

PREVENTION OF DIROPHILARIOSIS
Administered within the month of the host's activity (mosquito), it has demonstrated persistent efficacy during the seasonal period of risk of filariosis caused by D. immitis and skin lesions caused by D. repens in Europe.

Prolonged release

More details

447,00 € tax incl.

Add to wishlist

COMPOSITION
Moxidectin 3.4 mg / ml

PHARMACEUTICAL FORM
Powder, solvent for suspension for injection + adapter
ROUTE OF ADMINISTRATION
Subcutaneous injection
INDICATIONS
Prevention of filariosis (larvae L3 and L4 of Dirofilaria immittis).

Prevention of skin lesions and dermatitis caused by Dirofilaria repens (larvae L3).

Treatment of infections caused by larvae or adults of Ancylostomum caninum and Uncinaria stenocephala present at the time of treatment.

 

DOSE
0.17 mg moxidectin / kg body weight at a single dose, equivalent to 0.05 ml of reconstituted suspension / kg body weight.

SPECIES
Dog
SUPPRESSION PERIOD
Not precise
PRESENTATION
20 ml reconstitution vial + adapter

No customer reviews for the moment.

Write a review

Afilaria 3.4 mg/ml

Afilaria 3.4 mg/ml

PREVENTION OF DIROPHILARIOSIS
Administered within the month of the host's activity (mosquito), it has demonstrated persistent efficacy during the seasonal period of risk of filariosis caused by D. immitis and skin lesions caused by D. repens in Europe.

Prolonged release

30 other products in the same category: